Another study found that RUNX3 expression is lost in non-small cell lung cancer (NSCLC), leading to the upregulation of CCL5 and CCL19 in NSCLC cells, which was associated with tumor-associated bone destruction [82]. Here, RUNX3 is linked to neoplasm.